British drugmaker Indivior weighs U.S. listing, annual sales rise

Opioid addiction treatment maker Indivior is exploring a secondary listing in the United States, its biggest market, after the British company posted a better than expected rise in annual sales buoyed by its newer injectable therapy. Read More